OncoScreen™ IO is a pan-cancer test for tissue sample and detects important immune-oncology biomarkers including TMB and MSI, as well as rare but clinically actionable biomarkers, such as NTRK fusions, which provide important insights for therapy selection.

Cancer:

Bladder Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Solid Tumor

Gene:

MSI (Microsatellite instability), NTRK (Neurotrophic receptor tyrosine kinase), PD-L1 (Programmed death ligand 1), TMB (Tumor Mutational Burden)

Drug:

Cejemly (sugemalimab)

Method:

Next-Generation Sequencing (NGS)

TEST:OncoScreen™ IO

Details

TEST:
OncoScreen™ IO